Bli medlem
Bli medlem

Du är här


Medivir: Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen

Press Release 21 December 2015

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today
announces that the development of AL-704 (also known as JNJ-54257099)
has been terminated following completion of phase I clinical studies
conducted by Alios Biopharma Inc., one of the Janssen Pharmaceutical
Companies. These studies demonstrated that AL-704 was safe, well
tolerated and had acceptable pharmacokinetic properties. However its
clinical antiviral activity in persons infected with HCV genotype 1
was insufficient to justify further clinical studies. No further
compounds arising from Medivir's license agreement with Janssen on
HCV NS5B polymerase inhibitors are expected to be progressed into
clinical studies, and therefore no further revenues from this
agreement will be received.

Termination of this project does not affect the MIV-802 project, which
is wholly owned by Medivir, nor any of the products or compounds in
other partnerships with Janssen.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Richard Bethell, EVP Discovery Research Medivir AB, mobile: +46 (0)
727 043 211

Medivir is required under the Securities Markets Act to make the
information in this press release public.

The information was submitted for publication at 8.30 CET on 21
December 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research
focus on infectious diseases and oncology. We have a leading
competence within protease inhibitor design and nucleotide/nucleoside
science and we are dedicated to develop innovative pharmaceuticals
that meet great unmet medical need. Our commercial organization
provides a growing portfolio of specialty care pharmaceuticals on the
Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.